Skip to main content
OpenTrials
Completed

NCT Number: NCT05012696

Physiological Effects of Non-invasive Mechanical Ventilation Versus High-flow Nasal Cannula in Critically Ill Patients at High Risk of Extubation Failure

Weaning is one of the most complex challenges in mechanically ventilated patients. Increased work of breathing after extubation would play a central role in weaning failure. Currently, non-invasive ventilation (NIV) is recommended to prevent weaning failure in high-risk patients. On the other hand, high-flow nasal cannula (HFNC), which is a novel system capable of administering gas mixtures (air and oxygen) with a flow of up to 60 liters/min, has been used to prevent weaning failure in this kind of patients. The use of NIV and HFNC after extubation has been evaluated in some clinical studies. However, the evidence is controversial, and the information regarding the physiological effects that each therapy induces in recently extubated patients at high risk of weaning failure is lacking.

The goal of this proposal is to compare the acute physiological effects of postextubation NIV versus HFNC in critically ill patients at high risk of weaning failure on relevant mechanisms related to weaning failure: Work of breathing, lung function, ventilation distribution, systemic hemodynamics.

This will be a randomized crossover study that will include critically ill mechanically ventilated patients, who fulfill criteria indicating they may be ready for weaning from mechanical ventilation, and in whom a spontaneous breathing trial (SBT) is planned to determine if they should be extubated. After checking eligibility and obtaining informed consent, patients will be monitored with an esophageal catheter (esophageal/gastric pressures to determine work of breathing, and electric activity of diaphragm to determine neuromechanical coupling), and a noninvasive ventilation monitor (electric impedance tomography to assess global and regional ventilation). Work of breathing, lung function, and systemic hemodynamics will be assessed during the SBT. Inclusion in the study will be confirmed only if they pass the SBT and are extubated. During the first 2 hours after extubation, patients will undergo one hour of NIV and one hour of HFNC, with the crossover sequence being randomized previously at the time of inclusion and with assessments repeated at the end of each treatment period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Clínico UC Christus

Santiago, Santiago Metropolitan, 114D, Chile

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mechanical ventilation (MV) through an orotracheal tube for at least 48 hours
  • PaO2 /FiO2 ratio ≤ 300 mmHg (during the MV period)
  • Potential for weaning
  • Precipitating cause leading to MV in resolution
  • PaO2 /FiO2 ratio ≥ 150 mmHg
  • PEEP ≤ 8 cmH2O
  • pH > 7,25
  • SpO2 ≥ 90% with FiO2 ≤ 0.4; BPM ≤35
  • Hemodynamic stability (noradrenaline ≤ 0.1mcg / kg / min and SBP 90-160; HR <140)
  • Temperature <38 ° C
  • Presence of inspiratory effort and appropriate spontaneous cough
  • Decision to perform a spontaneous breathing trial by the attending physician
  • High risk of weaning failure defined by a history of: (i) Previous failed extubation, (ii) Chronic heart or respiratory failure, or (iii) MV ≥ 7 days.

Exclusion criteria

  • Contraindications to NIV or HFNC, which include abnormalities, trauma or surgery of the face or nose.
  • Contraindications for esophageal balloon catheter insertion (eg. severe coagulopathy, esophageal varices, and history of esophageal or gastric surgery)
  • Contraindication for use of electric impedance tomography (eg. Pacemaker)
  • Tracheostomy
  • Refusal to participate by the attending physician
  • Do not resuscitate order

Treatment and study plan

Non-invasive ventilation (NIV)

Device

Non-invasive ventilation will be provided through a mechanical ventilator (Carina, Dräger) through a facial interface (Fitlife Respironics, Philips). A PEEP level between 5 and 10 cmH2O, minimal pressure-support level of 5 cm H2O targeting a tidal volume around 6 to 8 ml/kg and at the same FiO2 applied during the spontaneous breathing trial.

High-flow nasal cannula

Device

High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher & Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.

Primary outcomes

  1. Pressure time-product (PTP) per minute

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Pressure time-product (PTP) per minute (cmH2O x s/min)

  2. Esophageal pressure swings (ΔPes)

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Esophageal pressure swings (ΔPes) defined as the absolute differences between end-expiratory and end-inspiratory Pes

  3. End-expiratory lung impedance (EELI)

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    End-expiratory lung impedance (EELI)assessed with Electric impedance tomography

Secondary outcomes

  1. Pressure time-product per breath

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Pressure time-product per breath (cmH2O x s). PTP will be assessed through an esophageal Neurovent catheter.

  2. Peak electric activity of the diaphragm (EAdi)

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Peak electric activity of the diaphragm (EAdi) EAdi will be measured in uV through a Neurovent catheter connected to a Servo-i ventilator

  3. Neuroventilatory efficiency

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Neuroventilatory efficiency is a parameter derived from the EAdi signal and the ventilation

  4. Diaphragmatic neuromuscular coupling

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Diaphragmatic neuromuscular coupling Pdi/EAdi

  5. Global inhomogeneity index

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula ]

    Index derived from EIT and calculated from the sum of the impedance changes of each pixel with respect to its median (in absolute values), divided by the sum of the impedance values of each pixel

  6. PaO2 / FiO2 ratio

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Parameter of oxygen exchange calculated as the ratio of PaO2 / FiO2

  7. PaCO2

    Time frame: 60 minutes after starting Non-invasive ventilation or high flow nasal cannula

    Arterial partial pressure of CO2 (PaCO2) Parameter of alveolar ventilation

Sponsors and collaborators

Lead sponsor

Pontificia Universidad Catolica de Chile

Other

Collaborators

  • Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Registry information

Official study title

Postextubation Non-invasive Ventilation Versus High-flow Nasal Cannula in Critically Ill Patients at High Risk of Weaning Failure: a Physiologic Randomized Crossover Study

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Aug 19, 2021
Registry last updated
Dec 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.